Dr. Spigel on Potential Advancements in Targeted Therapy in NSCLC

Supplements And Featured Publications, 2021 Year in Review: Updates in Biomarker-Driven Lung Cancer, Volume 1, Issue 1

In Partnership With:

Partner | Cancer Centers | <b>Sarah Cannon</b>

David Spigel, MD, discusses potential upcoming developments in targeted therapies for non–small cell lung cancer.

David Spigel, MD, chief scientific officer, director, the Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses potential upcoming developments in targeted therapies for non–small cell lung cancer (NSCLC).

Targeted therapies against HER2 and TROP2 have produced recent intriguing data, which could lead to accelerated approval strategies in NSCLC, Spigel says. By the end of 2022, multiple antibody-drug conjugates could become FDA approved for the HER2 and TROP2 populations, depending on the results of ongoing phase 3 trials, Spigel explains.

Over the next few years, data will also mature and read out on several clinical trials involving immunotherapy agents in the neoadjuvant and adjuvant settings, which could also shift the treatment paradigm, Spigel concludes.